Autopsy report · NCT03180762
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants
Cause of deathSafety
“Trial stopped: A SAE has occured. As a measure of precaution, the trial has been stopped.”
Life of this trial
- Ran for about 4 months before it stopped.
- 36 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry
- Conditions
- Healthy
- Interventions
- JNJ-64140284 0.1 mg; JNJ-64140284 0.5 mg; JNJ-64140284 2.5 mg; JNJ-64140284 10 mg; JNJ-64140284 50 mg; JNJ-64140284 150 mg
- Participants
- 36
- Sites
- 1
- Countries
- Belgium
Trials that died the same way
- Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP
“The trial was stopped earlier than planned after an ad hoc interim analysis” - Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
“The trial was stopped for futility in view of the results of the anticipated analysis” - A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer
“Decision was made by Sponsor to stop the trial.” - Ph1 Study of Valortim and Doxycycline in Humans
“Sister trial has SAE investigation underway - sponsor elected to withdraw as study expected to be repeated later” - Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
“Trial stopped for futility”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.